TY - JOUR. T1 - Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a. T2 - Results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II). AU - Patti, Francesco. AU - Amato, Maria Pia. AU - Trojano, Maria. AU - Bastianello, Stefano. AU - Tola, Maria Rosalia. AU - Picconi, Orietta. AU - Cilia, Sabina. AU - Cottone, Salvatore. AU - Grimaldi, Luigi M E. PY - 2012/9. Y1 - 2012/9. N2 - Purpose To report longitudinal changes in and explore the influence of cognition on social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS). Methods Italian patients (18-50 years) with RRMS and Expanded Disability Status Scale (EDSS) score ≤4.0 were assigned to interferon β-1a, 44 or 22 μg subcutaneously three times weekly, and underwent annual assessments for social functioning (Environmental Status Scale [ESS]) over 3 years. Results Baseline total ESS ...

The primary objective of the study is to determine which baseline and yearly response factors (clinical and para clinical) predict overall disease-free status at Month 12 and Month 24, and clinical disease-free status in subsequent Months 36 and 48. The secondary objectives are: To identify prognostic factors at Baseline that predict overall disease-free status at Month 12, and to assess if yearly overall disease-free response factors predict overall disease-free status at Month 24; To evaluate clinical disease-free status (relapse, Expanded Disability Status Scale [EDSS]) at each analysis time point of Months 12, 24, 36, and 48; To identify prognostic factors at Baseline that predict clinical disease-free status at Month 12, and to assess yearly clinical disease-free response factors that predict clinical disease-free status (relapse, EDSS) in subsequent years at Months 24, 36, and 48; To evaluate the impact of Tysabri at each analysis time point of Months 12, 24, 36, and 48 on the following: ...

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...

Objective: To determine whether high-dose immunosuppressive therapy followed by autologous hematopoietic stem cell transplantation (HDIT/AHSCT) induces sustained remissions and prevents loss of neurologic function in active relapsing-remitting multiple sclerosis (RRMS). Background: HDIT/AHSCT has been assessed as a possible new therapeutic strategy in severe forms of MS. Small uncontrolled studies showed that about 60% to 70% of treated patients do not worsen in the follow-up period of at least 3 years. Responses were best in those with earlier disease stages. Since degenerative changes may contribute to loss of neurologic function in progressive MS, HDIT/AHSCT is being studied in RRMS. Methods: HALT-MS is an ongoing phase 2 clinical trial of HDIT/AHSCT with high-dose chemotherapy (BEAM) and antithymocyte globulin (ATG) in active RRMS (EDSS score, 3.0-5.5; =2 relapses on treatment and EDSS score worsening over past year). This is followed by transplantation with autologous CD34+-selected cells ...

Incomplete recovery from relapses in individuals with relapsing-remitting multiple sclerosis (RRMS) contributes to stepwise disability worsening, underscoring

Plegridy (peginterferon beta-1a) is the first pegylated interferon indicated for the treatment of relapsing-remitting multiple sclerosis (MS).

Five years after treatment, nearly 70% of patients with relapsing-remitting multiple sclerosis showed no signs of disease progression.

TY - JOUR. T1 - Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis. AU - Tsantes, E.. AU - Curti, E.. AU - Ferraro, D.. AU - Lugaresi, A.. AU - Baldi, E.. AU - Montepietra, S.. AU - Immovilli, P.. AU - Simone, A. M.. AU - Mancinelli, L.. AU - Strumia, S.. AU - Vitetta, F.. AU - Foschi, M.. AU - Ferri, C.. AU - Ferrarini, C.. AU - Sola, P.. AU - Granella, F.. N1 - Funding Information: E.T. reports personal fees and non‐financial support from Merck & Co., personal fees from Almirall, personal fees and non‐financial support from Roche, non‐financial support from Biogen, non‐financial support from Sanofi, non‐financial support from Novartis, outside the submitted work. E.C. reports personal fees and non‐financial support from Merck & Co., personal fees and non‐financial support from Novartis, non‐financial support from Biogen, non‐financial support from Teva Pharmaceutical Industries, non‐financial ...

The RR-MS disease effect was relatively restricted and most of the mRNAs tested were not different from the normal controls. However, there were significant differences identified in the expression of a subset of mRNAs, including 13 with inflammatory/immune functions that could be relevant to MS. Th …

Abstract Despite the existence of therapeutic guidelines, management of multiple sclerosis relapse remains heterogeneous. Optimisation of relapse outcome demands an improved understanding of the neurologists therapeutic attitude towards relapse management, which is the aim of this study. Neurologists from 13 multiple sclerosis centres completed a questionnaire every time they assessed multiple sclerosis relapses. The questionnaire requested a guided description of the relapses clinical characteristics and an indication of the prescribed therapy, supported with up to 3 out of 20 suggested reasons. Over 3 months, 368 questionnaires were collected. Median percentage (%) of 21 relapses resulting in a prescription was 88.9%. Corticosteroids represented the most frequent prescription. A short-course of high-dose intravenous methylprednisolone was the most used corticosteroid (73.7%). Treatment was administrated mainly in day case unit (80.0%) and at home (13.6%). A tapered therapy was prescribed to ...

of Myelin and Maintenance of Axonal Conduction in the MOG-induced EAE Mouse Model (Poster Session I -- P1.220; April 28; 3:00 p.m. EDT) -- Anti-murine CD52 Antibody Treatment Does Not Adversely Affect the Migratory Ability of Immune Cells (Poster Session I -- P1.222; April 28; 3:00 p.m. EDT) -- Successful Detection and Management of Immune Thrombocytopenia in Alemtuzumab-Treated Patients with Active Relapsing-Remitting Multiple Sclerosis (Poster Session II -- P2.198; April 29; 7:30 a.m. EDT) -- Thyroid Autoimmune Adverse Events in Patients Treated with Alemtuzumab for Relapsing-remitting Multiple Sclerosis: Four-year Follow-up of the CARE-MS Studies (Poster Session II -- P2.199; April 29; 7:30 a.m. EDT) -- Safety of Using Disease-modifying Therapy Post-alemtuzumab Treatment in Patients With Relapsing-remitting Multiple Sclerosis in the Core and Extension Phases of CAMMS223, CARE-MS I, and CARE-MS II Studies (Poster Session II -- P2.201; April 29; 7:30 a.m. EDT) -- Alemtuzumab Has Similar ...

In the mid-1990s Beutler, in collaboration with Jack Sipe, a neurologist at Scripps, ran several clinical trials exploring the utility of cladribine in multiple sclerosis, based on the drugs immunosuppressive effects. Sipes insight into MS, and Beutlers interest in MS due to his sister having it, led a very productive collaboration.[18]:17[22] Ortho-Clinical, a subsidiary of J&J, filed an NDA for cladribine for MS in 1997 but withdrew it in the late 1990s after discussion with the FDA proved that more clinical data would be needed.[23][24] Ivax acquired the rights for oral administration of cladribine to treat MS from Scripps in 2000,[25] and partnered with Serono in 2002.[24] Ivax was acquired by Teva in 2006,[26][27] and Merck KGaA acquired control of Seronos drug business in 2006.[28] An oral formulation of the drug with cyclodextrin was developed[29]:16 and Ivax and Serono, and then Merck KGaA conducted several clinical studies. Merck KGaA submitted an application to the European ...

There is a paucity of knowledge concerning erythrocytes in the aetiology of Multiple Sclerosis (MS) despite their potential to contribute to disease through impaired antioxidant capacity and altered haemorheological features. Several studies have identified an abundance of erythrocyte miRNAs and variable profiles associated with disease states, such as sickle cell disease and malaria. The aim of this study was to compare the erythrocyte miRNA profile of relapsing-remitting MS (RRMS) patients to healthy sex- and age-matched controls. Erythrocytes were purified by density-gradient centrifugation and RNA was extracted. Following library preparation, samples were run on a HiSeq4000 Illumina instrument (paired-end 100 bp sequencing). Sequenced erythrocyte miRNA profiles (9 patients and 9 controls) were analysed by DESeq2. Differentially expressed miRNAs were validated by RT-qPCR using miR-152-3p as an endogenous control and replicated in a larger cohort (20 patients and 18 controls). After logarithmic

There is a paucity of knowledge concerning erythrocytes in the aetiology of Multiple Sclerosis (MS) despite their potential to contribute to disease through impaired antioxidant capacity and altered haemorheological features. Several studies have identified an abundance of erythrocyte miRNAs and variable profiles associated with disease states, such as sickle cell disease and malaria. The aim of this study was to compare the erythrocyte miRNA profile of relapsing-remitting MS (RRMS) patients to healthy sex- and age-matched controls. Erythrocytes were purified by density-gradient centrifugation and RNA was extracted. Following library preparation, samples were run on a HiSeq4000 Illumina instrument (paired-end 100 bp sequencing). Sequenced erythrocyte miRNA profiles (9 patients and 9 controls) were analysed by DESeq2. Differentially expressed miRNAs were validated by RT-qPCR using miR-152-3p as an endogenous control and replicated in a larger cohort (20 patients and 18 controls). After logarithmic

BACKGROUND: The cerebellum is of potential interest for understanding adaptive responses in motor control in patients with multiple sclerosis because of the high intrinsic synaptic plasticity of this brain region. OBJECTIVE: To assess the relative roles of interactions between the neocortex and the cerebellum using measures of functional connectivity. METHODS: A role for altered neocortical-cerebellar functional connectivity in adaptive responses to injury from multiple sclerosis was tested using 1.5 T functional magnetic resonance imaging (fMRI) during figure writing with the dominant right hand in patients with predominantly early relapsing-remitting multiple sclerosis. RESULTS: Patients (n = 14) showed a more bihemispheric pattern of activation in motor cortex than healthy controls (n = 11). Correlations between task related signal changes in neocortical and cerebellar regions of interest were used as a measure of functional connectivity. Healthy controls showed strong functional connectivity between

Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis ...

Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and neurodegenerative disorder. Since acetylcholine (ACh) is known to participate in the inflammatory response, we investigated the possible relationship between pro-inflammatory cytokines and acetylcholine levels in relapsing-remitting multiple sclerosis (RR-MS) patients. Levels of ACh and pro-inflammatory cytokines IL1-β and IL-17 were measured both in cerebrospinal fluid (CSF) and sera of 22 RR-MS patients in the relapsing phase and in 17 control subjects affected by other non-neurological diseases (OND). We observed higher levels of pro-inflammatory cytokines such as IL-1β and IL-17 in both CSF and serum of RR-MS patients compared to control subjects. Moreover, ACh levels were lower in CSF and serum of RR-MS patients compared to levels of control subjects. Although the relationship between high inflammatory cytokine levels and low ACh levels need to be further investigated in the future, our data suggest that IL-1β, and

To date, the only disease-modifying therapies shown to be effective in relapsing-remitting MS are the β-interferons (1, 2) and copolymer 1 (3). These therapies reduce relapse frequency by about one third and may slow disability progression. In this interesting Austrian study by Fazekas and colleagues, several comments are in order. Previous attempts at IVIg therapy in MS have yielded mixed results, and most studies have been uncontrolled or unblinded (4, 5). The primary end point in this study was the difference in the absolute change in EDSS score between groups rather than relapse frequency. These changes were very modest, although statistically significant. The authors chose to measure disability level at the end of the study rather than the more conservative sustained disability change, and this would tend to overstate the likelihood of progression in both treatment groups. Finally, magnetic resonance imaging was not done. Nonetheless, the findings from this work strongly suggest the need ...

Multiple sclerosis (MS) treatment in Latin America is a dynamic process due to the approval of new drugs worldwide, with particular emphasis on oral drugs at this moment. The introduction of these drugs in Latin American countries tends to be gradual, using data from local pharmacovigilance programs and often based on studies carried out in other continents. The potential patient population in the region presenting relapsing-remitting MS (RRMS) is estimated to be of the order of 50,000 people1, while its prevalence varies between 1.48 and 25 per 100, 000 inhabitants2-8. The main objectives of the present study were to update the therapeutic algorithm designed in 20109 and to assess the use of medications in several countries of the region. The present study focused on the first, second, and third-line therapeutic options, while a detailed and updated discussion on MS diagnosis can be found elsewhere10.. A literature search was carried out at PubMed database, using the key words multiple ...

Conclusion: SLCLA at 2.5% and 1.25% contrast levels correlates with retinal morphology and P100 latency and predicts some aspects of vision-related QoL in MS. More importantly, using a prospective cross-sectional approach we provide evidence that extending the MSFC by SLCLA as an additional visual component increases the performance of MSFC to capture MS-related disability. Longitudinal data on the relation between SLCLA, MSFC, and QoL will be available in the near future. (Source: BMC Neurology)

Be between 18 and 60 years of age. - Have definite relapsing multiple sclerosis. - Have had one or more relapses within the prior 12 months. - Must be in a clinically stable or improving neurological state during the four weeks prior to Study Day 1. - Expanded Disability Status Scale (EDSS) score from 0 to 5.5, inclusive. - If female, she must either be post-menopausal or surgically sterilized; or use a hormonal contraceptive, intra uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study; and be neither pregnant nor breast-feeding. - Confirmation that the subject is not pregnant must be established by a negative serum human chorionic gonadotropin (hCG) pregnancy test within 7 days of Study Day 1 and a negative urine pregnancy test on Study Day 1. A pregnancy test is not required if the subject is post-menopausal or surgically sterilized. - Be willing and able to comply with the protocol for the duration of the study. - Voluntarily provide written ...

CONCLUSION: GA showed to be a cost-effective treatment option for the prevention of relapses in Spanish patients diagnosed with RRMS. When GA in monotherapy is compared with INF in monotherapy and IFN+GA combined, it may be concluded that the first is the dominant strategy. PMID: 24494728 [PubMed - as supplied by publisher] (Source: Methods of Information in Medicine)

Relapsing-remitting is the most common form of multiple sclerosis. Learn about symptoms, causes, diagnosis, long-term treatments, prognosis, and more.

VÉCSEI László. [Recent data suggest that long-term worsening is common in relapsing-remitting multiple sclerosis patients and is largely independent of relapses or new lesion formation on brain MRI. The current definition of secunder progressive multiple sclerosis is worsening of disability independent of relapses over at least 6-month interval. Early focal inflammatory disease activity and spinal cord lesion are predictors of very-long term disease outcomes in relapse - onset multiple sclerosis. The potential of PET imaging to visualize hidden inflammation in MS brain in vivo is an important contribution for better understanding the progression of the disease. Therefore, PET imaging is a promising tool in detecting the conversion from relapsing remitting multiple sclerosis to secunder progressive form of multiple sclerosis. Furthermore, neuro-axonal damage is the pathological substrate of permanent disability in different neurological disorders including multiple sclerosis. The neurofilament ...

Healthcare decision-making is complex and involves a wide range of factors. For the payer, Spanish NHS, it is very relevant to use a rational criterion when allocating resources, which is based on clinical evidence, efficiency and budget impact of the different therapeutic options available for the management of a given disease [14, 15]. In the case of MS, the availability of several drugs for its treatment, each with its particularities and specific profile, makes choosing the most appropriate treatment not easy for physicians, patients, or the payer.. In Spain, MS treatment drugs are dispensed at the hospital pharmacy. Pharmacological direct costs of management of this disabling disease accounts for 52% of all resources required for its management and directly impacts on the cost of each hospital [16]. The average budget impact for the cohort of patients with RRMS under treatment in Spain, considering all the options indicated for first-line treatment, represents an investment of €260 ...

Gilenya has been approved in the EU for people with highly active relapsing-remitting multiple sclerosis (RRMS) despite treatment with beta interferon, or in patients with rapidly evolving severe RRMS.. The oral treatment showed superior efficacy to interferon beta-1a IM, a commonly prescribed treatment, reducing relapses by 52% (p,0.001) at one year. Two-year, placebo-controlled study demonstrated that Gilenya significantly reduced the risk of disability progression. The European Commission has granted Novartis approval for Gilenya® (fingolimod) 0.5 mg daily as a disease-modifying therapy in patients with highly active relapsing-remitting multiple sclerosis (RRMS) despite treatment with beta interferon, or in patients with rapidly evolving severe RRMS.. Today marks an important step forward in the way we manage this chronic, debilitating disease in Europe, said Professor Hans-Peter Hartung, Professor and Chairman, Dept. of Neurology, Heinrich-Heine University, Germany.. Gilenya is the first ...

Background Magnetic resonance imaging (MRI) is the best biomarker of inflammatory disease activity in relapsing remitting Multiple Sclerosis (RRMS) so far but the association with disability is weak. Appearance of new MRI-lesions is used to evaluate response to immunotherapies in individual patients as well as being the most common primary outcome in phase-2 trials. Measurements of brain atrophy show promising outcomes in natural cohort studies and some phase-2 trials. From a theoretical perspective they might represent irreversible neurodegeneration and be more closely associated with disability. However, these atrophy measurements are not yet established as prognostic factors in real-life clinical routine. High field MRI has improved image quality and resolution and new methods to measure atrophy dynamics have become available. Objective To investigate the predictive value of MRI classification criteria in to high/low atrophy and inflammation groups, and to explore predictive capacity of two

abnormalities acquisition advanced affects agent aims allows although analytically assess assessment asymmetric automated barrow blood bolus bottom brain capillary cerebral characterization characterize characterized clinical combined common complementary completed complex comprehensive consistent contrast correlate critical curves debilitating decreased derived detection determination diameter disability disease disorder dose dynamic dynamics dysfunction earliest early echoes enable enabling enhanced equations establish extrapolated five flair flow full functional gradient green heterogeneity impairment important included indicate induced inflammation inflammatory injection institute knowledge known life macro male measures mechanism metric metrics micro million moreover multitude neurological neurology numerous occur ongoing particularly passage pathogenesis patient patients peak people perfusion permeability permits phoenix play post precise preliminary prior progression protocol quality ...

PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the central nervous system (CNS) that is a leading cause of disability in young adults.The treatment of relapsing forms of MS is reviewed here, primarily focused on d

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) initiated by autoreactive CD4+ T cell recognizing and responding to myelin antigens. Our understanding of the immunopathogenesis of MS implicates T cell activation as an important step in the pathogenesis of this autoimmune disease. In experimental autoimmune encephalomyelitis (EAE), the animal model of MS, treatment of animals with CTLA4Ig, a fusion protein that binds and blocks B7 interaction with CD28, suppresses EAE.. We also found that expression of CD28 in the CNS of mice undergoing EAE correlated with disease activity. More importantly, B7 molecules are expressed in plaques from MS brain. Initial studies in humans with CTLA4Ig for the treatment of psoriasis showed that this treatment could safely be administered to patients and appeared to be efficacious.. Our hypothesis is that treatment with CTLA4Ig will arrest the disease if administered early in the course of MS and provides a novel conceptual ...

Loonstra FC, Hoitsma E, van Kempen ZL, Killestein J, Mostert JP. COVID-19 in multiple sclerosis: The Dutch experience. Mult Scler. 2020 Sep;26:1256-1260. van Gorp DAM, van der Hiele K, Heerings MAP, Jongen PJ, van der Klink JJL, Reneman MF, Arnoldus EPJ, Beenakker EAC, van Eijk JJJ, Frequin STFM, de Gans K, Hoitsma E, Mostert JP, Verhagen WIM, Zemel D, Visser LH, Middelkoop HAM. (2019) Cognitive functioning as a predictor of employment status in relapsing-remitting multiple sclerosis: a 2-year longitudinal study. Neurol Sci. 40: 2555-2564. Hiele K, Gorp van DAM, Heerings MAP, Jongen PPJ, Klink van der JJL, Beenakker EAC, Eijk van JJJ, Frequin STFM, Geel van BM, Hengstman GHD, Hoitsma E, Mostert JP, Verhagen WIM, Gans de K, Zemel D, Middelkoop HAM, Visser LH. (2019) Caregiver strain among life partners of persons with mild disability due to relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders 31: 5-11. Voortman M, Beekman M, Drent M, Hoitsma E, de Vries J. (2018) ...

Evidence is accumulating on the involvement of B lymphocytes in the pathophysiology of MS. The contribution of B-cells and their secreted products to MS may relate to the abilities of B-cells to (1) differentiate into plasmocytes that produce antibodies; (2) function as antigen-presenting cells, contributing to T-cell activation; (3) produce effector cytokines that may modulate the local immune environment; (4) harbour the Epstein-Barr virus in a chronically activated state; and (5) play a role in the formation and maintenance of new lymphoid foci within the CNS (Waubant 2008). In people with RRMS, B-cells are critical for T-cell trafficking into the CNS and may alter the process by influencing chemokine production within the CNS (Piccio 2010). Interleukin-6 (IL-6) secretion is a major mechanism of B-cell driven pathogenesis in experimental autoimmune encephalomyelitis (EAE) and MS (Barr 2012). B-cell depletion affects antibody production, cytokine networks, and B-cell mediated antigen ...

Researchers foresee not only a DMT in B-cell depletion but also a way to reduce the number of reinfusions that reduce disease activity.11 Such was the case in an uncontrolled, open-label study of 102 patients treated with rituximab for a mean of 2.4 years.11 In the dual-site study by Novi and colleagues, patients were reinfused with rituximab 375 mg/m2 based on a prespecified percentage of memory B cells and not on an every-6-month schedule, as had been the standard approach.11 A year before the start of rituximab therapy, the ARR was 0.67; 3 years after initiating rituximab therapy, the ARR decreased to 0.01.11 ...

This study assessed the real-life safety and efficacy of natalizumab in Hungarian patients with relapsing-remitting multiple sclerosis (RRMS).

Despite considerable success with agents that substantially reduce relapse frequency in the initial inflammatory, relapsing-remitting phase, over half of people eventually develop non-relapsing, secondary progressive MS 1 to 2 decades after the onset of relapsing-remitting MS. While a variety of symptomatic treatments is available, progression in secondary progressive MS is currently intractable, and immunomodulatory strategies used for relapsing-remitting MS have not proven effective when extended into secondary progressive MS (for example, beta interferon). Direct neuroprotection strategies (for example tetrahydrocannabinol) have also been ineffective. The critical and as yet unmet challenge therefore is to find effective and well-tolerated treatments for secondary progressive MS ...

Cognitive impairment differs between primary progressive and relapsing-remitting MS ABSTRACT Objectives: To characterize the cognitive abilities of patients with primary progressive multiple sclerosis (PPMS) and relapsing-remitting multiple sclerosis (RRMS) compared with healthy controls (HCs) matched for age, sex, and education ...

Looking for online definition of glatiramer acetate in the Medical Dictionary? glatiramer acetate explanation free. What is glatiramer acetate? Meaning of glatiramer acetate medical term. What does glatiramer acetate mean?

METHODS: In this multicentre, cohort study, we collected data about patients (age ≥16 years old) with clinically isolated syndrome, relapsing-remitting multiple sclerosis, and progressive multiple sclerosis. Patients were recruited from centres in Spain, Italy, France, Germany, Czech Republic, Netherlands, Canada, and the USA, with the first cohort starting in 2008 and the latest cohort starting in 2013. We assessed disability worsening using the Expanded Disability Status Scale (EDSS). The pRNFL thickness and macular volume were assessed once at study entry (baseline) by optical coherence tomography (OCT) and was calculated as the mean value of both eyes without optic neuritis for patients without a history of optic neuritis or the value of the non-optic neuritis eye for patients with previous unilateral optic neuritis. Researchers who did the OCT at baseline were masked to EDSS results and the researchers assessing disability with EDSS were masked to OCT results. We estimated the association ...

Venous angioplasty in multiple sclerosis: neurological outcome at two years in a cohort of relapsing-remitting patients. Fabrizio Salvi, MD, PhDa. Ilaria Bartolomei, MDa. Elena Buccellato, PharmDa. Roberto Galeotti, MDb. Paolo Zamboni, MDc. a Center for Rare and Neuroimmunological Diseases, Department of Neurological Science, Bellaria. Hospital, Bologna, Italy. b Vascular and Interventional Radiology Unit, S. Anna Hospital, Ferrara, Italy. c Vascular Diseases Center, University of Ferrara, Ferrara, Italy. Corresponding author: Fabrizio Salvi Center for Rare and Neuroimmunological Diseases Department of Neurological Science. Bellaria Hospital via Altura 3, 40139, Bologna, Italy. E-mail: [email protected] Summary. An open study was conducted with the aim of reporting long-term clinical outcome of endovascular treatment for chronic cerebrospinal venous insufficiency (CCSVI) in patients with multiple sclerosis (MS).. Twenty-nine patients with clinically definite relapsing-remitting MS ...

0007]The following references identify the numbers indicated above. [0008]1. Platten, M., and L. Steinman. 2005. Multiple sclerosis: trapped in deadly glue. Nature Medicine 11:252-253. [0009]2. Oksenberg, J. R., S. E. Baranzini, L. F. Barcellos, and S. L. Hauser. 2001. Multiple sclerosis: genomic rewards. Journal of neuroimmunology 113:171-184. [0010]3. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43:655-661. [0011]4. 1998. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352:1498-1504. [0012]5. Johnson, K. P., B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein, R. P. Lisak, L. W. Myers, H. S. Panitch, J. W. Rose, and R. B. Schiffer. ...

Benign multiple sclerosis (BMS) occurs in about 15% of patients with relapsing-remitting multiple sclerosis (RRMS) that over time do not develop significant neurological disability. The molecular events associated with BMS are not clearly understood. This study sought to underlie the biological mechanisms associated with BMS. Blood samples obtained from a cohort of 31 patients with BMS and 36 patients with RRMS were applied for gene expression microarray analysis using HG-U133A-2 array (Affymetrix). Data were analyzed by Partek and pathway reconstruction was performed by Ingenuity for the most informative genes (MIGs). We identified a differing gene expression signature of 406 MIGs between BMS patients, mean±SE age 44.5±1.5 years, 24 females, 7 males, EDSS 1.9±0.2, disease duration 17.0±1.3 years, and RRMS patients, age 40.3±1.8 years, 24 females, 12 males, EDSS 3.5±0.2, disease duration 10.9±1.4 years. The signature was enriched by genes related RNA polymerase I (POL-1) transcription, general

WESTON, Mass.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) announced positive data from the Phase 3 DEFINE clinical trial of oral BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS). Results showed that 240 mg of BG-12, administered either twice a day (BID) or three times a day (TID), significantly reduced the proportion of patients who relapsed by 49 percent and 50 percent, respectively, at two years compared with placebo.

According to the results of a new clinical trial, stem cell transplants are likely to induce remission of multiple sclerosis in the long run. The trial indicates that high-dose immunosuppressive therapy and transplantation of an individuals own stem cells may stimulate sustained reduction of relapsing-remitting multiple sclerosis. After five years of receiving high-dose immunosupprresive therapy treatment and autologous hematopoietic cell transplant, 69 percent of the participants did not experience continued disability. Additionally, they did not suffer from progression of MS symptoms or a relapse. Noteworthy, after obtaining HDIT/HCT, participants did not take any medication. Some studies have noted that the success rates of the present MS drugs are lower.. The National Institute of Allergy and Infectious Diseases (NIAID) were the sponsors of the trial dubbed HALT-MS. Immune Tolerance Network, which is funded by NIAID, conducted the research. The researchers published both the initial ...

The remarkable clinical efficacy of anti-CD20 monoclonal antibodies (mAb) in relapsing-remitting multiple sclerosis points at the critical involvement of B cells in the disease. However, the exact pathogenic contribution of B cells is poorly understood. In this publication we review new data on the role of CD20+ B cells in a unique experimental autoimmune encephalomyelitis (EAE) model in common marmosets (Callithrix jacchus), a small-bodied neotropical primate. We will also discuss the relevance of these data for MS. Different from rodent EAE models, but similar to MS, disease progression in marmosets can develop independent of autoantibodies. Progressive disease is mediated by MHC class Ib (Caja-E) restricted cytotoxic T cells, which are activated by γ-herpesvirus-infected B cells and cause widespread demyelination of cortical gray matter. B-cell directed monoclonal antibody therapies (anti-CD20 versus anti-BLyS and anti-APRIL) have a variable effect on EAE progression, which we found ...

Dear Editor, Takotsubo cardiomyopathy (TTC) has been universally regarded as a unique form of reversible myocardial dysfunction associated with a variety of emotional and physical stressors. In their recently published elegant article, DellAquila et al. have reported an interesting case of TTC triggered by an exacerbation of relapsing-remitting multiple sclerosis (MS). However, we would like to comment on this interesting case and its particular implications ...

WESTON, Mass.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) announced new data from studies evaluating oral BG-12 (dimethyl fumarate), which provide further evidence supporting its strong clinical and radiological effects in people with relapsing-remitting multiple sclerosis (RRMS) and reinforce its favorable safety profile seen to date. These data were presented at the 28th Congress of the European Committee for the Treatment and Research of Multiple Sclerosis (ECTRIMS) in Lyon, France.

TY - JOUR. T1 - Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. AU - Perumal, J. S.. AU - Caon, C.. AU - Hreha, S.. AU - Zabad, R.. AU - Tselis, A.. AU - Lisak, R.. AU - Khan, O.. PY - 2008/7. Y1 - 2008/7. N2 - Background: A short course of intravenous methylprednisolone (IVMP) followed by oral prednisone taper (OPT) is often used for the treatment of relapses in multiple sclerosis (MS). We examined the effect of IVMP plus OPT compared with IVMP only on neurologic disability 1 year after treatment of a relapse in patients with relapsing-remitting multiple sclerosis. Methods: Two hundred eighty-five consecutive relapses were analyzed in a retrospective fashion. One hundred fifty-two patients with a total of 171 relapses received IVMP plus an OPT at the time of relapse whilst 112 patients who experienced 114 relapses received IVMP without OPT. Results: There was no difference between the two groups in the baseline ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) announced that five-year results from the ENDORSE Phase 3 extension study show TECFIDERA® (dimethyl fumarate) provides strong and sustained efficacy in a broad range of people living with relapsing-remitting multiple sclerosis (RRMS). These data will be presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS).

Objective: To investigate accidental falls and near fall incidents in people with multiple sclerosis with respect to clinical variables and the predictive values of four tests. Design: A longitudinal, multi-centred cohort study with prospectively collected falls. Procedures: Self-reported incidents during the three months following a standardized test procedure. Subjects: Seventy-six people with multiple sclerosis and an Expanded Disability Status Scale score between 3.5 and 6.0. Main outcome measures: Berg Balance Scale, Timed Up and Go cognitive, Four Square Step Test (FSST) and 12-item Multiple Sclerosis Walking Scale. Results: Forty-eight people (63%) registered 270 falls. Most falls occurred indoors during activities of daily life. We found a correlation of r(s) = 0.57 between near falls and falls, and of r(s) = 0.82 between registered and retrospectively recalled falls. Fallers and non-fallers differed significantly regarding Expanded Disability Status Score (odds ratio (OR) 1.99, 95% ...

Immunotherapy with Interferon-beta (IFN beta) results in remarkably beneficial effects in patients with relapsing-remitting multiple sclerosis (MS), although the mechanisms by which it exerts these beneficial effects remain poorly understood. An investigation was made of the effects of IFN beta on pro-inflammatory and anti-inflammatory cytokine production in peripheral blood cells in MS patients, both untreated and those undergoing immunotherapy. as well as in healthy controls. Results show a significant increase in the production of pro-inflammatory cytokines such as TNF alpha, IFN gamma and IL-12 in the plasma and in the supernatant of leukocyte cultures from MS patients with the untreated disease; IFN beta administration significantly reduced the levels of TNF alpha and IFN gamma, with no changes in the level of IL-12. The Interferon-beta therapy also led to a significant increase in the production of IL-10, as well as a slight increase in that of TGF beta. The reduction in pro-inflammatory ...

New cases of central nervous system demyelination and exacerbations of pre-existing disease have been reported in patients with rheumatoid arthritis following exposure to TNF inhibitors. However, as in the case of lymphoma, any causal relationship remains controversial and unproven. In fact, TNF-a has been implicated in the pathogenesis of multiple sclerosis, and because of this there have been studies of TNF inhibitors in this disease. In a Phase I open-label study, two patients with rapidly progressing multiple sclerosis refractory to high-dose intravenous corticosteroids were treated with intravenous infliximab. Both patients were found to have an increase in the number of gadolinium-enhancing lesions on MRI, together with increases in CSF leucocyte counts after each infusion. However, these changes were not accompanied by neurological deterioration (van Oosten et al. 1996). In a Phase II multicentre study, 168 patients with relapsing-remitting and secondary progressive multiple sclerosis ...

Subjects. All patients had relapsing-remitting multiple sclerosis and were participants in 1 of 2 clinical trials, CAMMS-223 and CAMMS-224 (Cambridge UK Research Ethics Committee [REC 02/315 and 03/078]), in which alemtuzumab (supplied by Genzyme) is given by intravenous infusion of 12-24 mg/d for 5 days, followed by retreatment at 12 months. Patients and controls consented to venesection for research purposes (studies were approved by Cambridge UK Research Ethics Committee [LREC 02/263]) and all were free from exposure to other disease-modifying agents, including steroids, for at least 1 month at the time of blood sampling. For each experiment, all available samples, from all relevant patients, at all possible time points were used; there was no subgroup selection. More samples were available for serum studies, as retrospective frozen samples could be used. Assays of lymphocyte biology could not be performed on many patients shortly after alemtuzumab due to their profound lymphopenia. All DNA ...

July 31, 2014 , Appeals , Employment & Labor , Insurance Coverage The plaintiff in this case was employed by BDP International as an air import coordinator. Her full time sedentary job required her to sit for most of an eight hour day and, occasionally, to lift or carry a small amount of weight.. After she was diagnosed with relapsing-remitting multiple sclerosis (MS) in the late 1990s, she suffered an exacerbation in May 2005 that caused her to experience difficulty walking, among other serious symptoms. As a consequence, her treating neurologist opined that she was no longer able to work in any capacity, and advised that she withdraw from work on a permanent basis.. The plaintiff stopped working and submitted a claim to BDPs long term disability plan. In September 2005, Hartford Life and Accident Insurance Company, which administered the BDP plan, determined that the plaintiff was qualified to receive long term disability benefits. In 2006, the Social Security Administration (SSA) ...

Glatiramer acetate: Find the most comprehensive real-world treatment information on Glatiramer acetate at PatientsLikeMe. 1182 patients with fibromyalgia, multiple sclerosis, major depressive disorder, generalized anxiety disorder, diabetes type 2, post-traumatic stress disorder, systemic lupus erythematosus, bipolar disorder, Parkinsons disease, panic disorder, rheumatoid arthritis, high blood pressure (hypertension), myalgic encephalomyelitis/chronic fatigue syndrome, persistent depressive disorder (dysthymia), epilepsy, amyotrophic lateral sclerosis, migraine, hypothyroidism, osteoarthritis, traumatic brain injury, asthma, bipolar II disorder, attention deficit/hyperactivity disorder, social anxiety disorder, high cholesterol (hypercholesterolemia), idiopathic pulmonary fibrosis, irritable bowel syndrome, psoriasis, gastroesophageal reflux disease or bipolar I disorder currently take Glatiramer acetate.

Zainab Ali Abbood, Nawfal Madi Sheaheed and 3Hayder Fadhil Lateef. ABSTRACT. Background: Multiple Sclerosis, a chronic inflammatory and neurodegenerative disease of the central nervous system, characterized by recurrent relapses of central nervous system inflammation ranging from mild to severely disabling. Relapses have treated with steroids to reduce inflammation and hasten recovery. However, the commonly used intravenous methylprednisolone in a dose 500mg_1000mg for 5days. Objectives: Assessment of relationship between the dose of intravenous methylprednisolone (500mg) and (1000mg) and side effects for treatment of patients with relapses of multiple sclerosis. Methods: A prospective case controlled study was carried on 40 patients who had multiple sclerosis relapse confirmed by kuratzke expanded disability status scale. Patients were divided into 2 groups first group involved 20 patients treated with (500 mg IV methylprednisolone) for 5 days. The second group involved 20 patients treated with ...

Multiple sclerosis is increasingly becoming a major health problem among women worldwide. The aim of the present study was to estimate prevalence of depression in women with multiple sclerosis and also to identify risk factors contributing to its development. This was a cross-sectional study of depression in a sample of 226 women with multiple sclerosis. The sample was recruited from an outpatient clinic in Tehran, Iran. Depression was assessed using the Beck Depression Inventory-II (BDI-II). Univariate and multiple logistic regression analyses were performed to examine the association between depression and independent variables. Overall, 91 women (40.2 %) had moderate to severe depression. The mean age of participants was 35.7 years (SD = 8.07). The results obtained from multiple logistic regression analysis showed that the disease course (OR for relapsing-remitting MS = 2.36, % 95 CI = 1.14-5.53, P = 0.46), the expanded disability status scale (OR for score of 5-8 = 4.88, % 95 CI = ...

MS and RA patient advocate, Lisa Emrich, shares news and information about living with multiple sclerosis and rheumatoid arthritis while working as a musician in Washington, DC.

Inter-individual variability in patient response to each of the available therapies for multiple sclerosis, combined with the variable course of disease, emphasizes the need for tools that help guide treatment choice in multiple sclerosis. The current study on Copaxone, a first-line DMT with a well-established favorable efficacy and safety profile, constitutes the largest pharmacogenetic study in multiple sclerosis reported to date (Additional file 1). A four-SNP signature was identified as associated with treatment response. Signature-positive Copaxone-treated RRMS patients demonstrated better response in multiple clinically meaningful measures, including ARR, MRI, and NEDA in two discovery RRMS cohorts. Improved ARRs were also observed in five independent RRMS cohorts but not in either placebo- or Avonex-treated RRMS patients, demonstrating the predictive as opposed to prognostic nature of the signature, and its specificity to Copaxone. The signature identified a ~10% subset of ...

Objectives: It was the aim of this study to evaluate if the quantitative intrathecal immunoglobulin G (IgG) synthesis correlates with the brain atrophy and the total lesion volume (TLV) in brain magnetic resonance imaging (MRI) of multiple sclerosis (MS) patients. Methods: A total of 50 patients with relapsing-remitting MS were included in this study. MRIs were performed and cerebrospinal fluid samples were collected during the diagnostic determination when patients were in remission without treatment. Results: At study baseline, IgG index values were elevated in 36 patients (72%), and oligoclonal IgG bands were positive in 42 of 50 patients (84%). Brain MRI was abnormal in 94% of patients, and, compared with healthy controls, brain atrophy was observed in MS patients. A positive correlation among IgG index, cerebrospinal fluid leukocyte count and TLV was observed; the Expanded Disability Status Scale correlated positively with TLV and the number of lesions, although a significant relationship ...

TY - JOUR. T1 - Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. AU - Jacobs, Lawrence D.. AU - Cookfair, Diane L.. AU - Rudick, Richard A.. AU - Herndon, Robert M.. AU - Richert, John R.. AU - Salazar, Andres M.. AU - Fischer, Jill S.. AU - Goodkin, Donald E.. AU - Granger, Carl V.. AU - Simon, Jack H.. AU - Alam, John J.. AU - Bartoszak, David M.. AU - Bourdette, Dennis N.. AU - Braiman, Jonathan. AU - Brownscheidle, Carol M.. AU - Coats, Michael E.. AU - Cohan, Stanley L.. AU - Dougherty, David S.. AU - Kinkel, Revere P.. AU - Mass, Michele K.. AU - Munschauer, Frederick E.. AU - Priore, Roger L.. AU - Pullicino, Patrick M.. AU - Scherokman, Barbara J.. AU - Weinstock-Guttman, Bianca. AU - Whitham, Ruth H.. PY - 1996/4/15. Y1 - 1996/4/15. N2 - The accepted standard treatment of relapsing multiple sclerosis consists of medications for disease symptoms, including treatment for acute exacerbations. However, currently there is no therapy that alters the ...

BACKGROUND First-line agents approved in the United States for treatment of relapsing multiple sclerosis (MS) include intramuscular interferon beta (IFNbeta)-1a, subcutaneous (SC) IFNbeta-1a, SC IFNbeta-1b, and SC glatiramer acetate. Intravenous mitoxantrone is the only agent approved for secondary progressive MS, progressive relapsing MS, and worsening relapsing MS. Intravenous natalizumab is approved for relapsing forms of MS generally in patients who have an inadequate response to, or are unable to tolerate, first-line therapies. Corticosteroids are commonly used to treat relapses. This paper reviews the incidence and management of common adverse events (AEs) associated with these treatments. METHODS MEDLINE and EMBASE were searched for clinical trials and other publications between 1985 and 2007 reporting AEs associated with MS therapies, using these search terms: multiple sclerosis, interferon, Avonex, Betaseron, Rebif, glatiramer, copolymer 1, Copaxone, mitoxantrone, natalizumab, adverse events.

This trial has compared the changes in disability progression in multiple sclerosis patients on Natalizumab (NTZ) standard interval dose (q4 weeks, SID) and on

TY - JOUR. T1 - Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis. AU - Biegler, Brian W.. AU - Yan, Shirley X.. AU - Ortega, Sterling B.. AU - Tennakoon, Deepani K.. AU - Racke, Michael K.. AU - Karandikar, Nitin J.. PY - 2006/11/1. Y1 - 2006/11/1. N2 - We have demonstrated that GA therapy induces a differential upregulation of GA-specific, cytotoxic/suppressor CD8+ T-cell responses in MS patients. We utilized a novel combination of flow sorting and anchored PCR to analyze the evolving clonal composition of GA-specific CD4+ and CD8+ T-cells. TCRβ chain analysis revealed the development of an oligoclonal GA-specific CD8+ repertoire with persistence of dominant clones over long periods. Interestingly, some sequences resembled published oligoclonal CD8+ TCR sequences from MS lesions. In contrast, GA-specific CD4+ responses were polyclonal and showed continual evolution of their repertoire. This clonotypic and functional analysis provides ...

TYSABRI is approved in 75 countries. In the United States, TYSABRI is indicated as monotherapy for the treatment of patients with relapsing forms of MS. TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML). When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. In the European Union, it is indicated as a single disease modifying therapy in highly active relapsing-remitting MS (RRMS) for adult patients who have high disease activity despite treatment with a beta interferon or glatiramer acetate or patients with rapidly evolving severe RRMS.. TYSABRI has advanced the treatment of MS patients with its established efficacy. Data from the Phase 3 AFFIRM trial, which was published in The New England Journal of Medicine, showed that after two years, TYSABRI treatment led to a 68 percent relative reduction (p,0.001) in the annualized relapse rate when compared with placebo and ...

As a chronic neurological condition, it should come as no surprise that multiple sclerosis can produce psychiatric problems. In fact, such psychiatric problems are sometimes even the first presentation of MS. In addition to being an inflammatory, demyelinating disease primarily affecting CNS white matter, it has also been shown to damage cortical gray matter. Unfortunately, this only broadens the kinds of psychiatric and cognitive symptoms such patients can exhibit: Psychiatric symptoms in MS are highly prevalent and frequently overlooked in clinical settings.12-14 In 1 study of relapsing-remitting patients with MS in remission, 95% reported significant psychiatric symptoms, most frequently dysphoria (79%), agitation (40%), anxiety (40%), and irritability (35%).. Major depression is particularly common, representing approximately 50 percent of those with MS, as opposed to 10-15 percent of the general population. Those with MS are much more likely to commit suicide than the general population. ...

Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system. The onset of Multiple Sclerosis usually occurs between the ages of 20 and 50.[1] Diagnosis:The process involves the use of MRI, Cerebrospinal Fluid Analysis and tests of cognitive function, eyesight and muscular strength. The clinical course that we will focus on is Relapsing-Remitting MS. This involves periods where symptoms will flare-up interspersed with periods where no, or very mild symptoms are present. Symptoms will not necessarily get worse over time, however flare-up periods may increase in length as the disease progresses.[2] Aetiology:The cause of MS remains vastly unknown, however several links to genetics, the environment and infectious agents have been established. Genetics: Several risk alleles have been identified within the human genome. Presence of these alleles increases an individuals susceptibility to MS. Links to ethnicity and gender have also been observed, with those of Caucasian decent ...

peginterferon beta-1a) for the long-term treatment of relapsing forms of multiple sclerosis (MS). Manufactured by Biogen Idec, this new medication is the 11th disease-modifying therapy (DMT) to be approved for MS since the early 1990s. Plegridy is given once every two weeks through a subcutaneous self-injection.. As with all of the approved DMTs for MS, Plegridy is not a cure, but does slow MS disease activity. It reduces the annual relapse rate (ARR) as well as the number and size of brain lesions (areas of inflammation) as seen on magnetic resonance imaging (MRI) scans. Additionally, Plegridy reduced the risk of 12-week confirmed disability progression, as measured by the Expanded Disability Status Scale (EDSS).. Please see MSAAs online news article for more information!. If links are disabled in this email - to read the full article, copy and paste the following into your web browser:. support.mymsaa.org/plegridy. ...

Multiple sclerosis (MS) is an immune-mediated demyelinating disease characterized by central nervous system (CNS) lymphocyte infiltration, abundant production of pro-inflammatory cytokines, and inappropriate activation of Th1 and Th17 cells, B cells, and innate immune cells. The etiology of MS is complex, and genetic factors contribute to disease susceptibility. Genome-wide association studies (GWAS) have revealed numerous MS-risk alleles in the IL-6/STAT3, IL-12/STAT4, and IL-23/STAT3-pathways implicated in the differentiation of Th1 and Th17 cells. In this study, we investigated the signaling properties of these pathways in T, B, and NK cells from patients with relapsing-remitting MS (RRMS) and healthy controls, and assessed the genetic contribution to the activity of the pathways. This revealed a great variability in the level of STAT-pathway molecules and STAT activation between the cell types investigated. We also found a strong donor variation in IL-6, IL-12, and IL-23 responsiveness of ...

TY - JOUR. T1 - Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing- remitting multiple sclerosis. AU - Zipp, Frauke. AU - Weller, Michael. AU - Calabresi, Peter A.. AU - Frank, Joseph A.. AU - Bash, Craig N.. AU - Dichgans, Johannes. AU - McFarland, Henry F.. AU - Martin, Roland. PY - 1998/1/1. Y1 - 1998/1/1. N2 - CD95/CD95 ligand interactions are critically involved in the negative regulation of peripheral T-cell responses. Here, we report that serum levels of soluble CD95 are significantly elevated in patients with relapsing remitting multiple sclerosis. In a transectional study, CD95 levels did not correlate with clinical disability or lesion formation on magnetic resonance imaging. Longitudinally, Expanded Disability Status Scale changes were associated with high CD95 levels. Interferon-β (IFNβ) treatment led to an initial increase and subsequent decline of serum CD95 levels. Interestingly, patients generating neutralizing antibodies to the drug had significantly higher ...

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) leading to demyelination and neurodegeneration. MS affects approximately 80,000 people in France, most of them being young adults with a sex ratio of female to male of 3:1. Approximately 85% of patients present with relapsing-remitting MS, characterized by acute attacks (relapses) followed by partial or full recovery (remission). Patients can manifest with a heterogeneous group of physical symptoms including changes in vision, weakness, dyscoordination, sensory loss or distortions, changes in bowel and bladder function and of non physical symptoms such as depression, fatigue and cognitive changes. The other 15% present a progressive course from the onset, with or without superimposed relapses. Progression of disease may eventually lead to severe physical and cognitive disabilities. The life expectency is decreased by approximately 10 years. Diagnosis is made according to the recent revised ...

Within 3 years, 31% of patients discontinued treatment, mainly for disease activity. No significant sustained blood analysis alteration was observed over time, apart from a decrease of cholesterol levels. After 3 years of treatment, mean Expanded Disability Status Scale (EDSS) scores increased by 0.4 points compared with baseline. The mean annual relapse rate was reduced compared with baseline. Patients with , or = 2 relapses in the previous 2 years and with baseline EDSS scores of , or = 2 had a longer estimated time to first relapse and to progression and first relapse, respectively. These results confirm the safety and suggest a sustained effectiveness of i.m. IFNbeta-1a, extending the reported follow-up period to 6.3 years, and hypothesize the presence of possible predictors of clinical outcome ...

Synthon has announced that it has successfully concluded the decentralised procedures for glatiramer acetate 40mg/ml pre-filled syringe for the treatment of relapsing forms of multiple sclerosis and received regulatory approval in Europe. Synthon received regulatory clearance in all 27 EU/EEA member states involved in the procedures.

Jolly, H., Simpson, K., Bishop, B., Hunter, H., Newell, C., Denney, D. and Oleen-Burkey, M. (2008) Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. Journal of Neuroscience Nursing. 40(4), p.232-239.. Abstract:. Patients with multiple sclerosis (MS) report a number of adverse events related to immunomodulator injections, including local injection-site reactions (LISRs). Reactions characterized by pain, swelling, redness, or inflammation have been experienced by patients who self-inject glatiramer acetate, interferon beta-1b, or interferon beta-1a. Although these reactions rarely are serious, they can foster negative attitudes about self-injection and undermine a patients commitment to treatment, especially in the early stages of therapy. This randomized crossover study of 50 patients who had initiated or restarted glatiramer acetate therapy within the 3 months before the study examined whether applying a warm compress to the injection site ...

Teva Provides Update on Glatiramer Acetate 40mg for Amyotrophic Lateral Sclerosis (ALS) GA 40 mg was safe and well tolerated in ALS patients; however, study did not meet primary end point

The fifth Chemical Information Retrieval class on October 22, 2009 started out with covering the new 3D structure viewer introduced recently at PLoS ONE to provide ideas for students doing a multimedia project this term. The current student answers to the chemistry publishing FAQ are then discussed. The reason for removing glatiramer acetate from ChemSpider is explained and a few databases (Wikipedia, PubChem, DrugBank) are visited that still contain the incorrect SMILES, 3D structure and related properties. An overview of an Open Access site (OAD) suggested by Bill Hooker is provided to suggest additional questions for the FAQ. Examples of questions discussed include primary and secondary sources, peer review, article level metrics (a PLoS ONE article on malaria is used as an example), citation searching, Impact Factors and whether one should use ones real name in the blogosphere. Databases Scirus, Web of Science and PubMed are also reviewed ...

(2000) Ciccarelli et al. Multiple sclerosis (Houndmills, Basingstoke, England). We determined whether positive ANA was related to response to rIFNss-1a in 62 relapsing-remitting MS patients. According to the presence of antinuclear antibodies (ANA) at baseline and during the f...

AMERICAN ACADEMY OF NEUROLOGY Via Eureka Alert MINNEAPOLIS - A drug used to treat multiple sclerosis (MS), alemtuzumab, was found to reverse some of the physical disability caused by the disease, according to new research published in the October 12, 2016, online issue of Neurology®, a medical journal of the American Academy of Neurology. Because it can cause serious side effects, alemtuzumab is generally used in people who have not responded well to other MS drugs; however, in this study it was used relatively early in the course of MS. The drug is used in relapsing-remitting MS, the most common form of the disease, in which symptoms alternate between sudden worsening and remission. While many MS drugs slow the progress of disability, there have been little data about the abi.... ...